Base de dados : MEDLINE
Pesquisa : D04.210.500.054.079.429.824.832 [Categoria DeCS]
Referências encontradas : 277 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 28 ir para página                         

  1 / 277 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28774334
[Au] Autor:Jeon WY; Kim OS; Seo CS; Jin SE; Kim JA; Shin HK; Kim YU; Lee MY
[Ad] Endereço:K-herb Research Center, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea.
[Ti] Título:Inhibitory effects of Ponciri Fructus on testosterone-induced benign prostatic hyperplasia in rats.
[So] Source:BMC Complement Altern Med;17(1):384, 2017 Aug 03.
[Is] ISSN:1472-6882
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Benign prostatic hyperplasia (BPH) is non-cancerous condition of enlargement of the prostate, a common occurrence in older men. The immature fruits of Poncirus trifoliata (L.) Rafinesque (Rutaceae), Ponciri Fructus are widely used in traditional oriental medicine for the therapy of various diseases. However, little is known about the mechanism underlying the pathogenesis of BPH. In the present study, we investigated the protective effects of a Ponciri Fructus extract (PFE) on the development of BPH in a in a rat model of BPH induced by testosterone propionate (TP). METHODS: Male Sprague Dawley rats were used as a model of BPH after its induction by daily subcutaneous injections of TP/corn oil, for a period of four weeks. PFE was administrated daily 1 h before TP/corn oil injection by oral gavage at a dose level of 200 mg/kg during the 4 weeks of TP/corn oil injections. All rats were sacrificed at the end of the experiment, we measured the relative prostate weight, the levels of testosterone and dihydrotestosterone (DHT), histological changes, activities of antioxidant enzymes (catalase, glutathione peroxidase, glutathione reductase, and superoxide dismutase), and expression of proliferating cell nuclear antigen (PCNA). In addition, we also measured the inhibition (%) of 5α-reductase in the prostatic tissue. RESULTS: Our findings indicate that PFE significantly inhibited the development of BPH; decreased the relative prostate weight, the level of testosterone and DHT in serum and prostatic tissue, prostatic hyperplasia, expression of PCNA, and increased the antioxidant enzymes. Moreover, PFE showed a weak inhibitory activity on 5α-reductase. CONCLUSIONS: These results suggest that PFE may be used as a therapeutic agent for BPH via antiproliferative and antioxidant effects.
[Mh] Termos MeSH primário: Antioxidantes/uso terapêutico
Fitoterapia
Extratos Vegetais/uso terapêutico
Poncirus
Próstata/efeitos dos fármacos
Hiperplasia Prostática/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Antioxidantes/metabolismo
Antioxidantes/farmacologia
Catalase/metabolismo
Colestenona 5 alfa-Redutase/metabolismo
Di-Hidrotestosterona/sangue
Modelos Animais de Doenças
Frutas
Glutationa Peroxidase/metabolismo
Glutationa Redutase/metabolismo
Masculino
Tamanho do Órgão
Extratos Vegetais/farmacologia
Antígeno Nuclear de Célula em Proliferação/metabolismo
Próstata/metabolismo
Próstata/patologia
Hiperplasia Prostática/induzido quimicamente
Hiperplasia Prostática/metabolismo
Ratos Sprague-Dawley
Superóxido Dismutase/metabolismo
Testosterona/sangue
Propionato de Testosterona
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Plant Extracts); 0 (Proliferating Cell Nuclear Antigen); 08J2K08A3Y (Dihydrotestosterone); 3XMK78S47O (Testosterone); EC 1.11.1.6 (Catalase); EC 1.11.1.9 (Glutathione Peroxidase); EC 1.15.1.1 (Superoxide Dismutase); EC 1.3.1.22 (Cholestenone 5 alpha-Reductase); EC 1.8.1.7 (Glutathione Reductase); WI93Z9138A (Testosterone Propionate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170901
[Lr] Data última revisão:
170901
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170805
[St] Status:MEDLINE
[do] DOI:10.1186/s12906-017-1877-y


  2 / 277 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28635053
[Au] Autor:Zou Y; Aboshora W; Li J; Xiao T; Zhang L
[Ad] Endereço:State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 214122, China.
[Ti] Título:Protective Effects of Lepidium meyenii (Maca) Aqueous Extract and Lycopene on Testosterone Propionate-Induced Prostatic Hyperplasia in Mice.
[So] Source:Phytother Res;31(8):1192-1198, 2017 Aug.
[Is] ISSN:1099-1573
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The inhibitory effect of maca extractant, lycopene, and their combination was evaluated in benign prostatic hyperplasia (BPH) mice induced by testosterone propionate. Mice were divided into a saline group, solvent control group and testosterone propionate-induced BPH mice [BPH model group, solvent BPH model group, benzyl glucosinolate group (1.44 mg/kg), maca group (60 mg/kg), lycopene treated (15, 5, and 2.5 mg/kg), maca (30 mg/kg) combine lycopene treated (7.5, 2.5, and 1.25 mg/kg), and finasteride treated]. Benzyl glucosinolate was used in order to evaluate its pharmacological activity on BPH to find out whether it is the major active component of maca aqueous extract. Finasteride was used as positive control. The compounds were administered once for 30 successive days. Compared with solvent BPH model group, BPH mice fed with maca (30 mg/kg) and lycopene (7.5 mg/kg) combination exhibited significant reductions in the prostatic index, prostatic acid phospatase, estradiol, testosterone, and dihydrotestosterone levels in serum. They also had similar histological compared with those aspects observed in the mice in the solvent control group. The results indicated that combination of maca and lycopene synergistically inhibits BPH in mice. Copyright © 2017 John Wiley & Sons, Ltd.
[Mh] Termos MeSH primário: Carotenoides/farmacologia
Lepidium/química
Extratos Vegetais/farmacologia
Hiperplasia Prostática/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Estradiol/sangue
Finasterida/farmacologia
Masculino
Camundongos
Camundongos Endogâmicos ICR
Hiperplasia Prostática/induzido quimicamente
Testosterona/sangue
Propionato de Testosterona
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Plant Extracts); 36-88-4 (Carotenoids); 3XMK78S47O (Testosterone); 4TI98Z838E (Estradiol); 57GNO57U7G (Finasteride); SB0N2N0WV6 (lycopene); WI93Z9138A (Testosterone Propionate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171003
[Lr] Data última revisão:
171003
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170622
[St] Status:MEDLINE
[do] DOI:10.1002/ptr.5838


  3 / 277 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28610993
[Au] Autor:Cordaro M; Impellizzeri D; Siracusa R; Gugliandolo E; Fusco R; Inferrera A; Esposito E; Di Paola R; Cuzzocrea S
[Ad] Endereço:Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres 31, 98166 Messina, Italy.
[Ti] Título:Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia.
[So] Source:Toxicol Appl Pharmacol;329:231-240, 2017 Aug 15.
[Is] ISSN:1096-0333
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Palmitoylethanolamide (PEA), a fatty acid amide-signaling molecule has well-known anti-inflammatory and neuroprotective effects. Nevertheless, PEA does not possess the ability to prevent free radicals formation. Polydatin (PLD), a biological precursor of resveratrol, has antioxidant activity. A combination of PEA and PLD could, conceivably, have beneficial effects on oxidative stress produced by inflammatory processes. In the present study we investigated the effects of a co-micronized composite containing PEA and PLD (m(PEA/PLD)) in a model of testosterone-induced benign hyperplasia (BPH). BPH was provoked in rats by daily administration of testosterone propionate (3mg/kg) for 14days. This protocol leads to alterations in prostate morphology and increased levels of prostaglandin E2 and dihydrotestosterone as well as of 5α-reductase 1 and 5α-reductase 2 expression. Moreover, testosterone induced marked inflammation in terms of an increase in nuclear translocation of nuclear factor-κB p65 and consequently in IκB-α degradation as well as disregulation of inducible nitric oxide synthase, cyclooxygenase-2 and manganese superoxide dismutase expression and in the apoptosis pathway. Our results show, for the first time, that m(PEA/PLD) is capable of decreasing prostate weight and dihydrotestosterone production in BPH-induced rats. These effects were most likely correlated to the anti-inflammatory and apoptotic effects of m(PEA/PLD). Accordingly, these results support the view that m(PEA/PLD) should be further studied as a potent candidate for the management of BPH.
[Mh] Termos MeSH primário: Anti-Inflamatórios/farmacologia
Etanolaminas/farmacologia
Glucosídeos/farmacologia
Ácidos Palmíticos/farmacologia
Próstata/efeitos dos fármacos
Hiperplasia Prostática/tratamento farmacológico
Estilbenos/farmacologia
[Mh] Termos MeSH secundário: 3-Oxo-5-alfa-Esteroide 4-Desidrogenase/metabolismo
Animais
Anti-Inflamatórios/química
Antioxidantes/química
Antioxidantes/farmacologia
Apoptose/efeitos dos fármacos
Proteínas Reguladoras de Apoptose/metabolismo
Di-Hidrotestosterona/metabolismo
Dinoprostona/metabolismo
Modelos Animais de Doenças
Combinação de Medicamentos
Composição de Medicamentos
Etanolaminas/química
Glucosídeos/química
Mediadores da Inflamação/metabolismo
Masculino
Estresse Oxidativo/efeitos dos fármacos
Ácidos Palmíticos/química
Próstata/metabolismo
Próstata/patologia
Hiperplasia Prostática/induzido quimicamente
Hiperplasia Prostática/metabolismo
Hiperplasia Prostática/patologia
Ratos Sprague-Dawley
Transdução de Sinais/efeitos dos fármacos
Estilbenos/química
Propionato de Testosterona
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Antioxidants); 0 (Apoptosis Regulatory Proteins); 0 (Drug Combinations); 0 (Ethanolamines); 0 (Glucosides); 0 (Inflammation Mediators); 0 (Palmitic Acids); 0 (Stilbenes); 08J2K08A3Y (Dihydrotestosterone); 6R8T1UDM3V (palmidrol); EC 1.3.99.5 (3-Oxo-5-alpha-Steroid 4-Dehydrogenase); K7Q1JQR04M (Dinoprostone); WI93Z9138A (Testosterone Propionate); XM261C37CQ (polydatin)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170615
[St] Status:MEDLINE


  4 / 277 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28314523
[Au] Autor:Kwok KY; Choi TL; Kwok WH; Wong JK; Wan TS
[Ad] Endereço:Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T., Hong Kong, China. Electronic address: karen.y.kwok@hkjc.org.hk.
[Ti] Título:Detection of anabolic and androgenic steroids and/or their esters in horse hair using ultra-high performance liquid chromatography-high resolution mass spectrometry.
[So] Source:J Chromatogr A;1493:76-86, 2017 Apr 14.
[Is] ISSN:1873-3778
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Anabolic and androgenic steroids (AASs) are a class of prohibited substances banned in horseracing at all times. The common approach for controlling the misuse of AASs in equine sports is by detecting the presence of AASs and/or their metabolites in urine and blood samples using gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS). This approach, however, often falls short as the duration of effect for many AASs are longer than their detection time in both urine and blood. As a result, there is a high risk that such AASs could escape detection in their official race-day samples although they may have been used during the long period of training. Hair analysis, on the other hand, can afford significantly longer detection windows. In addition, the identification of synthetic ester derivatives of AASs in hair, particularly for the endogenous ones, can provide unequivocal proof of their exogenous origin. This paper describes the development of a sensitive method (at sub to low parts-per-billion or ppb levels) for detecting 48 AASs and/or their esters in horse hair using ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS). Decontaminated horse hair was pulverised and subjected to in-situ liquid-liquid extraction in a mixture of hexane - ethyl acetate (7:3, v/v) and phosphate buffer (0.1M, pH 9.5), followed by additional clean-up using mixed-mode solid-phase extraction. The final extract was analysed using UHPLC-HRMS in the positive electrospray ionisation (ESI) mode with both full scan and parallel reaction monitoring (PRM). This method was validated for qualitative identification purposes. Validation data, including method specificity, method sensitivity, extraction recovery, method precision and matrix effect are presented. Method applicability was demonstrated by the successful detection and confirmation of testosterone propionate in a referee hair sample. To our knowledge, this was the first report of a comprehensive screening method for detecting as many as 48 AASs and/or their esters in horse hair. Moreover, retrospective analysis of non-targeted AASs and/or their esters was made feasible by re-examining the full scan UHPLC-HRMS data acquired.
[Mh] Termos MeSH primário: Anabolizantes/análise
Androgênios/análise
Doping nos Esportes/prevenção & controle
Ésteres/análise
Cabelo/química
Cavalos
Esteroides/análise
[Mh] Termos MeSH secundário: Anabolizantes/química
Androgênios/química
Animais
Cromatografia Líquida de Alta Pressão
Ésteres/química
Cromatografia Gasosa-Espectrometria de Massas
Extração Líquido-Líquido
Espectrometria de Massas
Padrões de Referência
Estudos Retrospectivos
Extração em Fase Sólida
Esteroides/química
Propionato de Testosterona/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Anabolic Agents); 0 (Androgens); 0 (Esters); 0 (Steroids); WI93Z9138A (Testosterone Propionate)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170404
[Lr] Data última revisão:
170404
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170319
[St] Status:MEDLINE


  5 / 277 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28211173
[Au] Autor:Akanni OO; Abiola OJ; Adaramoye OA
[Ad] Endereço:Drug Metabolism and Toxicology Research Laboratories, Department of Biochemistry, College of Medicine, University of Ibadan, Ibadan, Nigeria.
[Ti] Título:Methyl Jasmonate Ameliorates Testosterone Propionate-induced Prostatic Hyperplasia in Castrated Wistar Rats.
[So] Source:Phytother Res;31(4):647-656, 2017 Apr.
[Is] ISSN:1099-1573
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Benign prostate hyperplasia (BPH) is a progressive disease that is related to age. Known therapeutic agents used in the treatment of BPH are associated with toxicity. Therefore, chemoprevention could be an effective approach. We investigated the ameliorative effects of methyl jasmonate (MeJA) in testosterone propionate (TP)-induced BPH in castrated rats. Castration was performed by removing both testes through the scrotum sack under ketamine anesthesia. Rats were assigned into seven groups of seven animals each: non-castrated control, castrated control, castrated rats that received TP, castrated rats that received TP and MeJA, castrated rats that received TP and finasteride, castrated rats that received MeJA, and castrated rats that received finasteride. Results indicate that BPH rats had significantly (p < 0.05) elevated prostate weight and relative weight of prostate relative to control. Also, BPH rats had significantly (p < 0.05) increased activities of prostatic acid and alkaline phosphatases, levels of zinc, and malondialdehyde. Further, levels of enzymic and non-enzymic antioxidative indices were significantly (p < 0.05) reduced in BPH. Histology of prostate revealed hyperplasia of transition lobe, increased expression of PSA, and Ki67 in BPH. Treatment with MeJA and finasteride attenuated the activities of the phosphatases and levels of antioxidants in BPH. Overall, MeJA ameliorates BPH via antioxidative mechanism. Copyright © 2017 John Wiley & Sons, Ltd.
[Mh] Termos MeSH primário: Acetatos/química
Ciclopentanos/química
Oxilipinas/química
Extratos Vegetais/química
Hiperplasia Prostática/tratamento farmacológico
Propionato de Testosterona/química
Testosterona/química
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Masculino
Ratos
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetates); 0 (Cyclopentanes); 0 (Oxylipins); 0 (Plant Extracts); 3XMK78S47O (Testosterone); 900N171A0F (methyl jasmonate); WI93Z9138A (Testosterone Propionate)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170503
[Lr] Data última revisão:
170503
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170218
[St] Status:MEDLINE
[do] DOI:10.1002/ptr.5778


  6 / 277 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28179209
[Au] Autor:Seara FAC; Barbosa RAQ; de Oliveira DF; Gran da Silva DLS; Carvalho AB; Freitas Ferreira AC; Matheus Nascimento JH; Olivares EL
[Ad] Endereço:Laboratory of Cardiovascular Physiology and Pharmacology, Department of Physiological Sciences, Institute of Biology, Federal Rural University of Rio de Janeiro, 23890-000 Seropedica, RJ, Brazil; Laboratory of Cardiac Electrophysiology, Carlos Chagas Filho Institute of Biophysics, Federal University
[Ti] Título:Administration of anabolic steroid during adolescence induces long-term cardiac hypertrophy and increases susceptibility to ischemia/reperfusion injury in adult Wistar rats.
[So] Source:J Steroid Biochem Mol Biol;171:34-42, 2017 Jul.
[Is] ISSN:1879-1220
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Chronic administration of anabolic androgenic steroids (AAS) in adult rats results in cardiac hypertrophy and increased susceptibility to myocardial ischemia/reperfusion (IR) injury. Molecular analyses demonstrated that hyperactivation of type 1 angiotensin II (AT1) receptor mediates cardiac hypertrophy induced by AAS and also induces down-regulation of myocardial ATP-sensitive potassium channel (K ), resulting in loss of exercise-induced cardioprotection. Exposure to AAS during adolescence promoted long-term cardiovascular dysfunctions, such as dysautonomia. We tested the hypothesis that chronic AAS exposure in the pre/pubertal phase increases the susceptibility to myocardial ischemia/reperfusion (IR) injury in adult rats. Male Wistar rats (26day old) were treated with vehicle (Control, n=12) or testosterone propionate (TP) (AAS, 5mgkg n=12) 5 times/week during 5 weeks. At the end of AAS exposure, rats underwent 23days of washout period and were submitted to euthanasia. Langendorff-perfused hearts were submitted to IR injury and evaluated for mechanical dysfunctions and infarct size. Molecular analysis was performed by mRNA levels of α-myosin heavy chain (MHC), ßMHC and brain-derived natriuretic peptide (BNP), ryanodine receptor (RyR2) and sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) by quantitative RT-PCR (qRT-PCR). The expression of AT1 receptor and K channel subunits (Kir6.1 and SURa) was analyzed by qRT-PCR and Western Blot. NADPH oxidase (Nox)-related reactive oxygen species generation was assessed by spectrofluorimetry. The expression of antioxidant enzymes was measured by qRT-PCR in order to address a potential role of redox unbalance. AAS exposure promoted long-term cardiac hypertrophy characterized by increased expression of ßMHC and ßMHC/αMHC ratio. Baseline derivative of pressure (dP/dt) was impaired by AAS exposure. Postischemic recovery of mechanical properties was impaired (decreased left ventricle [LV] developed pressure and maximal dP/dt; increased LV end-diastolic pressure and minimal dP/dt) and infarct size was larger in the AAS group. Catalase mRNA expression was significantly decreased in the AAS group. In conclusion, chronic administration of AAS during adolescence promoted long-term pathological cardiac hypertrophy and persistent increase in the susceptibility to myocardial IR injury possible due to disturbances on catalase expression.
[Mh] Termos MeSH primário: Envelhecimento
Anabolizantes/toxicidade
Androgênios/toxicidade
Cardiomegalia/induzido quimicamente
Vasos Coronários/efeitos dos fármacos
Coração/efeitos dos fármacos
Isquemia Miocárdica/induzido quimicamente
Traumatismo por Reperfusão Miocárdica/induzido quimicamente
[Mh] Termos MeSH secundário: Anabolizantes/administração & dosagem
Androgênios/administração & dosagem
Animais
Cardiomegalia/fisiopatologia
Catalase/antagonistas & inibidores
Catalase/genética
Catalase/metabolismo
Vasos Coronários/fisiopatologia
Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos
Coração/fisiopatologia
Injeções Intramusculares
Masculino
Isquemia Miocárdica/patologia
Isquemia Miocárdica/fisiopatologia
Traumatismo por Reperfusão Miocárdica/patologia
Traumatismo por Reperfusão Miocárdica/fisiopatologia
Miocárdio/enzimologia
Miocárdio/metabolismo
Miocárdio/patologia
Cadeias Pesadas de Miosina/química
Cadeias Pesadas de Miosina/genética
Cadeias Pesadas de Miosina/metabolismo
Distribuição Aleatória
Ratos Wistar
Espécies Reativas de Oxigênio/metabolismo
Propionato de Testosterona/administração & dosagem
Propionato de Testosterona/toxicidade
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anabolic Agents); 0 (Androgens); 0 (MYH7 protein, rat); 0 (Reactive Oxygen Species); EC 1.11.1.6 (Catalase); EC 3.6.4.1 (Myosin Heavy Chains); WI93Z9138A (Testosterone Propionate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170718
[Lr] Data última revisão:
170718
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170210
[St] Status:MEDLINE


  7 / 277 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28073285
[Au] Autor:Charous SJ; Hotaling JM; Burgess BD; Sappington JM; Park J; Turek G; Foecking EM
[Ad] Endereço:1 Loyola University of Chicago, Department of Otolaryngology-Head and Neck Surgery, Maywood, Illinois, USA.
[Ti] Título:Muscle-Nerve-Muscle Grafting for Facial Reanimation in Rats.
[So] Source:Ann Otol Rhinol Laryngol;126(4):261-267, 2017 Apr.
[Is] ISSN:1943-572X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Facial paralysis is a devastating condition leaving patients with a myriad of aesthetic and functional consequences. Muscle-nerve-muscle (MNM) neurotization is a reinnervation technique that involves implanting an autogenous nerve graft as a conduit between an innervated "donor" muscle and a denervated "recipient" muscle. We investigated the use of MNM reinnervation, alone or in combination with electrical stimulation (ES) and testosterone propionate (TP) in comparison to nerve reanastomosis (RE), on functional recovery following rat facial nerve injury. METHODS: Thirty-one male, Sprague-Dawley rats were assigned to groups: no graft (control), MNM grafting alone (MNM), MNM grafting with ES and TP (MNM+ES+TP), or RE. Harvested right facial nerve branches were used as the MNM graft. Functional recovery was assessed by behavioral observations and electromyographic recordings. RESULTS: The MNM grafting improved muscle tone and vibrissae movement. The ES+TP treatment further enhanced muscle tone as well as reduced recovery time for coordinated movement in a manner that is comparable to those of RE. Electromyographic recordings demonstrated electrical conductance across all MNM grafts. CONCLUSION: These data have important implications for patients with unilateral paralysis from facial or laryngeal nerve injury, particularly those who are not candidates for nerve reanastomosis.
[Mh] Termos MeSH primário: Androgênios/farmacologia
Terapia por Estimulação Elétrica/métodos
Músculos Faciais/fisiopatologia
Nervo Facial/cirurgia
Paralisia Facial/terapia
Transferência de Nervo/métodos
Propionato de Testosterona/farmacologia
[Mh] Termos MeSH secundário: Animais
Modelos Animais de Doenças
Eletromiografia
Músculos Faciais/efeitos dos fármacos
Músculos Faciais/inervação
Masculino
Tono Muscular/efeitos dos fármacos
Distribuição Aleatória
Ratos
Ratos Sprague-Dawley
Recuperação de Função Fisiológica/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgens); WI93Z9138A (Testosterone Propionate)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170417
[Lr] Data última revisão:
170417
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170112
[St] Status:MEDLINE
[do] DOI:10.1177/0003489416686587


  8 / 277 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27915587
[Au] Autor:Rejtharová M; Rejthar L; Cacková K
[Ad] Endereço:a USKVBL , Brno , Czech Republic.
[Ti] Título:Determination of testosterone esters and estradiol esters in bovine and porcine blood serum.
[So] Source:Food Addit Contam Part A Chem Anal Control Expo Risk Assess;34(4):477-481, 2017 Apr.
[Is] ISSN:1944-0057
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Monitoring of steroid esters in blood serum is desirable in order to detect the possible illegal use of natural hormones as growth promoters. A method for the determination of testosterone propionate, testosterone benzoate, testosterone isocaproate, testosterone decanoate and estradiol benzoate in bovine and porcine blood serum was developed. The procedure consists of protein precipitation and removal of phospholipids using a HybridSPE®-Phospholipid column followed by clean-up on a hydrophilic modified styrene polymer Supel -Select HLB column and LC-MS/MS measurement. The method was validated according to Commission Decision 2002/657/EC. Decision limits for all analytes were observed in the range 5-30 pg ml . The method was shown to be robust for bovine and porcine serum analyses and can be applied for both screening and confirmatory determination in routine residue monitoring.
[Mh] Termos MeSH primário: Cromatografia Líquida/normas
Estradiol/sangue
Espectrometria de Massas em Tandem/normas
Testosterona/sangue
[Mh] Termos MeSH secundário: Animais
Proteínas Sanguíneas/química
Bovinos
Precipitação Química
Di-Hidrotestosterona/análogos & derivados
Di-Hidrotestosterona/sangue
Estradiol/análogos & derivados
Guias como Assunto
Limite de Detecção
Fosfolipídeos/isolamento & purificação
Suínos
Testosterona/análogos & derivados
Propionato de Testosterona/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Proteins); 0 (Phospholipids); 08J2K08A3Y (Dihydrotestosterone); 1S4CJB5ZGN (estradiol 3-benzoate); 3XMK78S47O (Testosterone); 4TI98Z838E (Estradiol); IJW60LAO6S (testosterone decanoate); T74307G2D9 (stanolone benzoate); WI93Z9138A (Testosterone Propionate); X8ST05GYDM (testosterone isocaproate)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170308
[Lr] Data última revisão:
170308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161206
[St] Status:MEDLINE
[do] DOI:10.1080/19440049.2016.1268272


  9 / 277 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27889121
[Au] Autor:Sauls JA; Voelz BE; Hill SL; Mendonça LG; Stevenson JS
[Ad] Endereço:Department of Animal Sciences and Industry, Kansas State University, Manhattan 66506-0201.
[Ti] Título:Increasing estrus expression in the lactating dairy cow.
[So] Source:J Dairy Sci;100(1):807-820, 2017 Jan.
[Is] ISSN:1525-3198
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Using an activity monitoring system (AMS) equipped with an accelerometer, 2 experiments were conducted to test the hypotheses that (1) enhancing progesterone before inducing luteolysis or (2) exposing cows to estradiol cypionate (ECP) or testosterone propionate (TP) after luteolysis would increase occurrence and intensity of estrus. Our goal was to determine if more cows could be detected in estrus by an AMS compared with other estrus-detection aids. In experiment 1, cows (n=154) were fitted with both an AMS collar and a pressure-sensitive, rump-mounted device (HeatWatch; HW) and assigned to 3 treatments: (1) no CL + progesterone insert (CIDR) for 5d, (2) CL only, or (3) CL + 2 CIDR inserts for 5d to achieve a range in concentrations of progesterone. Prostaglandin F was administered to all cows upon CIDR insert removal or its equivalent. Progesterone concentration up to 72h posttreatment was greatest in CL + 2 CIDR, followed by CL only, and no CL + CIDR cows. Estrus occurred 14 to 28h earlier in no CL + CIDR compared with CL-bearing cows. Estrus intensity was greater for CL + 2 CIDR than for CL-only cows. The AMS and HW detected 70 and 59% of cows defined to be in estrus, respectively. In experiment 2, cows (n=203) were equipped with both an AMS and a friction-activated, rump-mounted patch (Estrotect patch) and assigned to receive 1mg of ECP, 2mg of TP, or control 24h after PGF . Concentrations of estradiol 24 and 48h after treatment were greater in ECP cows compared with controls. Estrus expression detected by AMS or patches in cows defined to be in estrus tended to be greater or was greater for ECP compared with controls, respectively. Compared with controls and in response to TP or ECP, estrus occurred 8 to 18h earlier and was of greater intensity for ECP cows, respectively. The AMS and patches determined 73 and 76% of cows defined to be in estrus, respectively. Of cows exposed to the AMS, HW, or patches, 70, 61, and 75%, respectively, were detected in estrus and more than 93% of these subsequently ovulated. In contrast, of the residual cows not detected in estrus, 62 to 77% ovulated in the absence of detected estrus. Only ECP was successful in inducing more expression and intensity of estrus, and proportions of cows detected in estrus exceeded 80%. Given the large proportion of cows equipped with AMS collars ovulating in the absence of estrus, further research is warranted to determine if more pregnancies can be achieved by inseminating those cows not detected in estrus at an appropriate time when PGF is administered to induce luteolysis.
[Mh] Termos MeSH primário: Estro/efeitos dos fármacos
Lactação
[Mh] Termos MeSH secundário: Animais
Bovinos
Dinoprosta/farmacologia
Estradiol/análogos & derivados
Estradiol/farmacologia
Detecção do Estro
Feminino
Luteólise/efeitos dos fármacos
Ovulação/efeitos dos fármacos
Progesterona/metabolismo
Propionato de Testosterona/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
4G7DS2Q64Y (Progesterone); 4TI98Z838E (Estradiol); 7E1DV054LO (estradiol 17 beta-cypionate); B7IN85G1HY (Dinoprost); WI93Z9138A (Testosterone Propionate)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161128
[St] Status:MEDLINE


  10 / 277 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27802175
[Au] Autor:Chaudhari NK; Nampoothiri LP
[Ti] Título:Neurotransmitter alteration in a testosterone propionate-induced polycystic ovarian syndrome rat model.
[So] Source:Horm Mol Biol Clin Investig;29(2):71-77, 2017 Feb 01.
[Is] ISSN:1868-1891
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Polycystic ovarian syndrome (PCOS), one of the leading causes of infertility seen in women, is characterized by anovulation and hyperandrogenism, resulting in ovarian dysfunction. In addition, associations of several metabolic complications like insulin resistance, obesity, dyslipidemia and psychological co-morbidities are well known in PCOS. One of the major factors influencing mood and the emotional state of mind is neurotransmitters. Also, these neurotransmitters are very crucial for GnRH release. Hence, the current study investigates the status of neurotransmitters in PCOS. MATERIALS AND METHODS: A PCOS rat model was developed using testosterone. Twenty-one-day-old rats were subcutaneously injected with 10 mg/kg body weight of testosterone propionate (TP) for 35 days. The animals were validated for PCOS characteristics by monitoring estrus cyclicity, serum testosterone and estradiol levels and by histological examination of ovarian sections. Neurotransmitter estimation was carried out using fluorometric and spectrophotometric methods. RESULTS: TP-treated animals demonstrated increased serum testosterone levels with unaltered estradiol content, disturbed estrus cyclicity and many peripheral cysts in the ovary compared to control rats mimicking human PCOS. Norepinephrine (NE), dopamine, serotonin, γ-amino butyric acid (GABA) and epinephrine levels were significantly low in TP-induced PCOS rats compared to control ones, whereas the activity of acetylcholinesterase in the PCOS brain was markedly elevated. CONCLUSION: Neurotransmitter alteration could be one of the reasons for disturbed gonadotropin-releasing hormone (GnRH) release, consequently directing the ovarian dysfunction in PCOS. Also, decrease in neurotransmitters, mainly NE, serotonin and dopamine (DA) attributes to mood disorders like depression and anxiety in PCOS.
[Mh] Termos MeSH primário: Modelos Animais de Doenças
Neurotransmissores/metabolismo
Síndrome do Ovário Policístico/metabolismo
Propionato de Testosterona/toxicidade
[Mh] Termos MeSH secundário: Animais
Dopamina/metabolismo
Epinefrina/metabolismo
Feminino
Teste de Tolerância a Glucose
Seres Humanos
Norepinefrina/metabolismo
Síndrome do Ovário Policístico/induzido quimicamente
Síndrome do Ovário Policístico/patologia
Ratos
Serotonina/metabolismo
Ácido gama-Aminobutírico/análogos & derivados
Ácido gama-Aminobutírico/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Neurotransmitter Agents); 1ZHM019FLD (4-amino-3-hydroxybutyric acid); 333DO1RDJY (Serotonin); 56-12-2 (gamma-Aminobutyric Acid); VTD58H1Z2X (Dopamine); WI93Z9138A (Testosterone Propionate); X4W3ENH1CV (Norepinephrine); YKH834O4BH (Epinephrine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170316
[Lr] Data última revisão:
170316
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161102
[St] Status:MEDLINE



página 1 de 28 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde